QureTech Bio competitors & alternatives

Pharmaceuticals

Synereca Pharmaceuticals, Inc. is a research-stage biopharmaceutical company based in Oklahoma City, Oklahoma, developing orally active compounds that restore the efficacy of existing antibiotics.

RECREO PHARMACEUTICALS LLCPharmaceuticalsUnited States

71% matchPrivate

Pharmaceuticals

Recreo Pharmaceuticals LLC is a healthcare company focused on developing and testing antibiotics to combat antibiotic resistance and improve patient health. The firm monitors industry trends and medical technology to advance its drug development initiatives.

Paratek PharmaceuticalsPharmaceuticalsUnited States

69% match

Pharmaceuticals

Paratek Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapies for complex medical conditions, focusing on infectious diseases and antimicrobial resistance. The company's product portfolio includes NUZYRA, an antibiotic for bacterial infections, and XHANCE, a nasal spray for chronic rhinosinusitis. These treatments are designed to serve adult patients with significant unmet medical needs.

SHANGHAI MICURX PHARMACEUTICAL CO., LTD.688373 · PharmaceuticalsChina

68% matchPublic

Pharmaceuticals

Shanghai MicuRx Pharmaceutical Co., Ltd. is a China-based biopharmaceutical company focused on developing novel antibiotics for serious bacterial infections, including drug-resistant infections. It developed contezolid (MRX-I), an oxazolidinone antibiotic intended for treatment of resistant Gram-positive bacterial infections, serving hospitals and infectious-disease patients.

Quest PharmaTech Inc.QPT · PharmaceuticalsCanada

67% matchPublic

Pharmaceuticals

Quest PharmaTech Inc. is a Canadian pharmaceutical company that develops products for targeted cancer therapy, including proprietary antibodies. The company operates and invests in various biotechnology ventures, holding ownership interests in firms focused on advancing immunotherapy treatments.

AicurisPharmaGermany

66% match

Pharma

AiCuris Anti-infective Cures AG is a biopharmaceutical company headquartered in Wuppertal, Germany. The company specializes in the research and development of innovative, life-saving anti-infective therapies designed to address critical needs in immunocompromised patients.

Venatorx PharmaceuticalsPharmaceuticalsUnited States

66% match

Pharmaceuticals

Venatorx Pharmaceuticals, Inc. is a pharmaceutical manufacturing company based in Malvern, Pennsylvania, focused on the discovery and development of novel anti-infective treatments.

RECCE PHARMACEUTICALS LTDRCE · Pharmaceuticals, Biotechnology & Life SciencesSydney, Australia

65% matchPublic

Pharmaceuticals, Biotechnology & Life Sciences

Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants. Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.

Protez PharmaceuticalsPharmaceuticalsUnited States

65% match

Pharmaceuticals

Protez Pharmaceuticals is a pharmaceutical and medical research company founded in 2003 and focused on the discovery and development of novel injectable and oral small molecule antibiotics for hospital-based, difficult-to-treat infections. The company was acquired by Novartis AG in June 2008.

CureAgePharmaUnited Kingdom

65% match

Pharma

CureAge Therapeutics is a biotechnology research company headquartered in London, United Kingdom. The firm is dedicated to discovering and advancing innovative therapeutic solutions.

Pharmaceuticals

TenNor Therapeutics (Suzhou) Limited specializes in researching, developing, and bringing to market unique therapies for illnesses arising from bacterial infections and bacterial metabolic functions. Its robust product pipeline includes Rifasutenizole (TNP-2198), designed to combat Helicobacter pylori infections. Another key asset, Rifaquizinone (TNP-2092), is being advanced in an injectable formulation to treat Periprosthetic Joint Infection (PJI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and infections associated with Left Ventricular Assist Devices (LVADs). An oral variant of TNP-2092 is aimed at addressing conditions linked to gut bacterial metabolism, such as Hepatic Encephalopathy (HE) and Irritable Bowel Syndrome with Diarrhea (IBS-D). Furthermore, their development programs feature a topical TNP-2092 for confronting drug-resistant bacterial strains and biofilm-mediated infections; TNBi-1, a novel narrow-spectrum small molecule for H. pylori; TNBi-2, a broad-spectrum, multi-targeting small molecule for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD); and TNBm-1, a broad-spectrum bifunctional small molecule for metabolic disorders. The company was established in 2012 and maintains its headquarters in Suzhou, China.

Pharmaceuticals

Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.